Alchemab Therapeutics
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
Total raised
€69M
€69,098,100
Funding rounds
2
Investors
7
distinct backers
Active since
2021-04
latest 2025-09
Funding by year
EUR raised per yearSignals
Medium confidenceRaise-next likelihood49
base rate 44% for Series A
- ▲ In typical raise window
- ▼ Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ €30M+ raised
- ▲ 7y since founding
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-09-09 | Series A | — | DCVC Bio,Lightstone Ventures,Lilly,Ono Venture Investment (OVI),RA Capital,SV Health Investors | View deal → |
| 2021-04-15 | Series A | €69M | RA Capital Management | View deal → |